18F-FDG Solution Buffering for Autoclave Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The radiochemical purity of 18F-FDG solutions decreases significantly during standard autoclaving steps and is further compromised by radiolysis, limiting its usability to less than 95% radiochemical purity, which fails to meet pharmacopeia specifications and is exacerbated by the short half-life of the radioisotope.
Innovation Solution
Incorporating a physiologically acceptable weak acid buffer, such as citrate, acetate, or ascorbate, into the 18F-FDG solution, maintaining a pH between 2 and 5.5, followed by autoclaving at temperatures between 110°C and 150°C, specifically optimized for the 18F radioisotope's stability and half-life, to maintain radiochemical purity and reduce radiolysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard autoclaving steps are applied to sterilize 18F-FDG solution, then sterilization is achieved, but radiochemical purity decreases drastically below 95%
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the 18F-FDG solution to a specific range (2.0-5.5, preferably 3.0-4.5) using buffers before autoclaving. This pH adjustment protects the radiochemical purity during autoclaving while still achieving sterilization, resolving the contradiction between sterilization effectiveness and radiochemical purity maintenance.
2Reliability
If autoclaving is performed at higher temperatures for longer duration to ensure sterilization, then sterilization effectiveness improves, but radiochemical purity and radioisotope stability deteriorate
Solution Approach 1:
The patent optimizes autoclaving parameters to a specific temperature range (110°C-150°C, preferably 130°C-140°C, most preferably 134°C) and duration (1-30 minutes, preferably 1-10 minutes, most preferably 2-5 minutes). Combined with pH buffering, these parameter changes achieve effective sterilization while maintaining radiochemical purity above 95% and accounting for the short half-life of the 18F radioisotope (109.8 minutes).
3Device complexity
If no buffer is added to 18F-FDG solution, then solution composition remains simple, but radiolysis occurs rapidly reducing usable period
Solution Approach 1:
The patent introduces buffers (weak acid buffers such as citrate, acetate, or ascorbate buffers at pH 2.0-5.5) as intermediary substances that protect 18F-FDG from radiolysis. These buffers act as mediators between the radioactive compound and the damaging radiation, significantly extending the usable period while maintaining radiochemical purity above 95% for at least 8 hours post-production.
4Manufacturing precision
If pH is adjusted to protect radiochemical stability, then radiochemical purity is maintained, but physiological acceptability may be compromised
Solution Approach 1:
The patent carefully selects pH values within the range of 2.0-5.5 (preferably 3.0-4.5) and uses physiologically acceptable buffers (citrate, acetate, or ascorbate buffers) that can tolerate this pH range. This optimized parameter selection maintains radiochemical purity while ensuring the solution remains suitable for pharmaceutical use and patient injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for autoclaving of 18F-FDG solutions to maintain radiochemical purity above 95% eight hours post-production, significantly reducing radiolysis and extending the usable period, as demonstrated by improved stability and radiochemical purity in buffered solutions compared to non-buffered controls.
Implementation Method 1
buffering the 18F-FDG-solution has a strong effect on the physical/chemical characteristics, i.e. the radiostability
Implementation Method 2
18F-FDG rapidly loses in radiochemical purity due to both radiolysis and the half-life of the radioisotope
Implementation Method 3
Autoclaving of the 18F-FDG-solution is performed at a temperature between 110° C. and 150° C., preferably at a temperature between 130° C. and 140° C. and more preferably at a temperature of 134° C.
Implementation Method 4
the half-life of the radioisotope, limiting the period in which the compound can be used
Data Source
AI summary
The invention relates to a method for improving one or more physical/chemical characteristics, like reduced radiolysis of and the ability to autoclave, a 18F-fluor-deoxy-glucose (18F-FDG)-solution, which method comprises the steps of a) provision of a 18F-fluor-deoxy-glucose (18F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the 18F-fluor-deoxy-glucose (18F-FDG)-solution. The invention also relates to a method for preparing a sterile 18F-fluor-deoxy-glucose (18F-FDG)-solution by autoclaving said 18F-fluor-deoxy-glucose (FDG)-solution.